Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that data from its Phase 1 study of varlilumab, a fully human monoclonal antibody targeting CD27, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 in Chicago. The abstracts accepted for poster presentation are listed below. In addition, the data will be discussed during a Poster Highlight Session entitled “Modulating the Anti-tumor Immune Response” by Dr. Cassian Yee of The University of Texas MD Anderson Cancer Center on Monday, June 2, 2014 from 5:15 to 5:30 p.m. CDT. Celldex Therapeutics, Inc. (NASDAQ:CLDX) weekly performance is 24.43%. On last trading day company shares ended up $15.74. Analysts mean target price for the company is $36.00. Celldex Therapeutics, Inc. (NASDAQ:CLDX) distance from 50-day simple moving average (SMA50) is -12.11%.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), announced the appointment of Chris Bowden, M.D., to the newly created position of chief medical officer, where he will oversee global clinical development and regulatory initiatives for Agios. Dr. Bowden, who brings more than 17 years of experience in clinical drug development, including the approval of several cancer medicines, was previously vice president, product development oncology, franchise lead (Signaling Group) at Genentech, Inc., a member of the Roche Group. Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares advanced 9.36% in last trading session and ended the day on $35.97. AGIO return on assets is -31.90%. Agios Pharmaceuticals Inc (NASDAQ:AGIO) quarterly performance is 15.33%.
Ruthigen, Inc (NASDAQ:RTGN) a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, announced that the underwriters of Ruthigen’s recently completed initial public offering have partially exercised their option to purchase additional shares of common stock. The underwriters have purchased an additional 154,290 shares from Ruthigen pursuant to the option. Ruthigen Inc (NASDAQ:RTGN) shares moved up 5.40% in last trading session and was closed at $6.64, while trading in range of $6.15 – $6.90. Ruthigen Inc (NASDAQ:RTGN) year to date (YTD) performance is -8.41%.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares hit a new 52-week low on Tuesday following a weaker than expected earnings announcement, American Banking News reports. The company traded as low as $33.02 and last traded at $33.06, with a volume of 73,091 shares trading hands. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) ended the last trading day at $35.26. Company weekly volatility is calculated as 6.88% and price to cash ratio as 19.84. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) showed a positive weekly performance of 0.34%.
Leave a Reply